Lung Cancer
CA266-0001: An open-label, two arms, randomized, Phase 3 study evaluating the efficacy, safety of BMS‑986545-01 versus durvalumab in participants with locally advanced, unresectable Stage III NSCLC, who have not progressed following definitive, platinum-based, concurrent chemoradiation therapy (ROSETTA Lung-201)
- Details
ClinicalTrials.gov ID:
NCT07361497
Diagnosis Type:
NA
USOR Number:
- Address
,
P: